WO2010034656A1

WO2010034656A1 - Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors

Info

Publication number: WO2010034656A1
Application number: PCT/EP2009/061965
Authority: WO
Inventors: Luca Gobbi; Georg Jaeschke; Rosa Maria Rodriguez Sarmiento; Lucinda Steward
Original assignee: F. Hoffmann-La Roche Ag
Priority date: 2008-09-23
Filing date: 2009-09-15
Publication date: 2010-04-01
Also published as: CN102164927A; US7825123B2; MX2011002755A; JP2012502948A; AU2009296055A1; EP2337783A1; KR20110076944A; CA2737252A1; US20100075981A1; IL211565A0; BRPI0919342A2

Abstract

The present invention relates to compounds of the general formula (I), having affinity and selectivity for the dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful for the therapeutic and/or prophylactic treatment of cognitive disorders.

Description

Isoxazolo[4,5lpyridin-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors

The present invention relates to compounds of the general formula I,

wherein:

R is Ci-₆-alkyl;

Ci-₆-alkyl substituted by one 3 to 6 membered monocyclic cycloalkyl or 1 to 3 halogens; Ci-₆-alkoxy; aryl; aryl substituted by 1 to 3 halogens; heteroaryl; or heteroaryl substituted by 1 to 3 halogens; as well as pharmaceutically acceptable salts thereof. It has been surprisingly found that the compounds of formula I have affinity for dopamine D3 receptors and thus are useful in the treatment of conditions wherein modulation, especially antagonism/inhibition, of D3 receptors is beneficial, e. g. to treat drug dependency or as antipsychotic agents.

Background Information Dopamine, a major catecholamine neurotransmitter, is involved in the regulation of a variety of functions which include emotion, cognition, motor functions, and positive reinforcement, (Purves, D. et al. (2004) Neuroscience. Sinauer, third edition, Sunderland, Massachusetts). The biological activities of dopamine are mediated through G protein- coupled receptors (GPCRs) and in human, five different dopamine receptors D_rD₅ have been identified, where the D₂-like receptors (D₂, D₃ and D₄) couple to the G-protein G_αi (Missale, C. et al.. ( 1998) Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225). The D₃ dopamine receptor is most highly expressed in the nucleus accumbens (Gurevich, E. V., Joyce, J. N. ( 1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20, 60-80), and is proposed to modulate the mesolimbic pathway consisting of neuronal projections from the ventral tegmental area, hippocampus and amygdala to the nucleus accumbens, which projects to the prefrontal and cingulate cortices as well as various thalamic nuclei.

SMU 16.04.2009 The limbic circuit is thought to be important for emotional behavior and thus D₃ receptor antagonists are proposed to modulate psychotic symptoms such as hallucinations, delusions and thought disorder (Joyce, J. N. and Millan, M. J., (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today, 1 JuI, Vol. 10, No. 13, 917-25), while these antagonists spare the D₂ modulated striatal extrapyramidal system (associated with EPS induction). In addition, it has been reported that drug naive schizophrenic patients show altered levels of D₃ receptor expression (Gurevich, E. V. et al. (1997) Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 54, 225-232) and dopamine release (Laruelle, M. (2000) Imaging dopamine dysregulation in schizophrenia: implication for treatment. Presented at Workshop Schizophr.: Pathol. Bases and Mech. Antipsychotic Action, Chicago), indicating that a disturbed homeostasis of dopamine plays an important role in the etiology of schizophrenic symptoms.

Detailed description of the invention

Compounds of formula I and its pharmaceutically acceptable salts have been found to be useful in the treatment of all aspects of drug dependency, including drug intake, relapse to drug-seeking behaviour following abstinence and withdrawal symptoms from drugs of abuse such as alcohol, cocaine, opiates, nicotine, benzodiazepines and inhibition of tolerance induced by opioids, as well as for the treatment of drug craving. It is also useful as an antipsychotic agent for example in the treatment of schizophrenia, schizoaffective disorders, schizophreniform diseases, psychotic depression (which term includes bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder and dysthymia, depressive disorders resulting from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion), anxiety disorders (which includes generalised anxiety and social anxiety disorder), mania, acute mania, paranoid and delusional disorders. The compounds are also useful for the treatment of a family of related disorders referred to as somatoform disorders, as well as for the treatment of premature ejaculation. The compounds are further useful for the treatment of attention-deficit hyperactivity disorder (ADHD), addiction (smoking cessation, cocaine and others) and obsessive compulsive disorder (OCD).

Compounds of formula I may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, salicylate, sulphate, pyruvate, citrate, lactate, mandelate, tartarate, and methanesulphonate. Preferred are the hydrochloride salts. Also solvates and hydrates of compounds of formula I and their salts form part of the present invention. Compounds of formula I can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.

It will be appreciated, that the compounds of general formula I in this invention may be derivatized at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.

As used herein, the term "Ci-₆-alkyl" is equal to the term "lower alkyl" and denotes monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butγ\ and the like. Preferred alkyl groups are groups with 1, 2, 3 or 4 carbon atoms. Most preferred alkyl groups are methyl and ethyl.

The phrase "Ci-6-alkyl substituted by" refers to lower alkyl, which is substituted by one or multiple substituents, preferably 1-5 substituents, selected from the group as specified for the specific "Ci-6-alkyl substituted by", i.e. for example halogen or cycloalkyl. Preferred substituents are fluoro and cyclopropyl. Preferred substituted Ci-6-alkyl are cyclopropyl-Ci-₆-alkyl, cycloalkyl-Ci-₆-alkyl, fluoro-Ci-₆-alkyl and halogen-Ci-₆-alkyl. Most preferred are cyclopropyl-ethyl and fluoro-methyl.

The term "halogen" denotes chlorine (Cl), iodine (I), fluorine (F) and bromine (Br). Preferred halogen is fluorine.

The term "Ci-6-alkoxy" denotes a group -O -R' wherein R' is Ci-6-alkyl as defined above. Preferred alkoxy group is methoxy-ethyl.

The phrase "3 to 6 membered monocyclic cycloalkyl" refers to a monovalent saturated monocyclic hydrocarbon radical of 3 to 6 ring carbon atoms. Examples are cyclopropyl, cyclobutanyl, cyclopentyl or cyclohexyl. Preferred examples are cyclopropyl, cyclopentyl and cyclohexyl. Preferred is cyclopropyl.

The term "aryl" refers to an aromatic carbocyclic group comprising 6 to 14, preferably 6 to 10, carbon atoms and having at least one aromatic ring or multiple condensed rings in which at least one ring is aromatic, for example phenyl (Ph), benzyl, naphthyl, biphenyl or indanyl. Preferred aryl group is phenyl. The phrase "aryl substituted by" refers to an aryl which is substituted by one or multiple substituents, preferably 1-4 substituents, whereby substitution at each ring atom individually is possible, with a substituent selected from the group as specified for the specific "aryl substituted by", i.e. for example amino, amino-lower alkyl, cyano, cyano- lower alkyl, halogen, halogen-lower alkyl, hydroxy, hydroxy-lower alkyl, lower alkoxy- lower alkyl, lower alkyl, lower alkoxy, halogen-lower alkoxy, (lower alkyl,lower alkyl)N-, - N(lower alkyl,H), N(lower alkyl,lower alkyl) -lower alkyl, N(lower alkyl,H) -lower alkyl, nitro, lower alkyl-S(O)2-, carboxy, carboxy-lower alkyl, lower alkyl-COO-lower alkyl, COO-lower alkyl, CO-N(lower alkyl,H) -lower alkyl, CO-N(lower alkyl,lower alkyl) -lower alkyl, CO-NH₂-lower alkyl, lower alkyl-CO- and the like. Preferred substituent is F. Preferred "aryl substituted by" are halogen-aryl, halogen-phenyl, fluoro-phenyl and fluoro- aryl. Most preferred is 4-fluoro-phenyl.

The term "heteroaryl", alone or in combination with other groups, refers to an aromatic carbocyclic group of having a single 4 to 8 membered ring or multiple condensed rings comprising 6 to 14, more preferably 6 to 10, ring atoms and containing 1, 2 or 3 heteroatoms, in which group at least one heterocyclic ring is aromatic. Examples of such groups include pyrrolyl, thienyl, furyl, pyrazolyl (pyrazyl), imidazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothiazolyl, benzotriazolyl, benzoimidazolyl, benzooxazinyl, benzothiazinyl, benzothienyl and the like. Preferred heteroaryl group is pyridinyl.

The phrase "heteroaryl substituted by" refers to a heteroaryl which is substituted by one or multiple substituents, preferably 1-4 substituents, whereby substitution at each ring atom individually is possible, selected from the group as specified for the specific "heteroaryl substituted by", i.e. for example amino, amino-lower alkyl, cyano, cyano-lower alkyl, halogen, halogen-lower alkyl, hydroxy, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl, lower alkoxy, halogen-lower alkoxy, (lower alkyl,lower alkyl)N-, (lower alkyl,H)N-, N(lower alkyl,lower alkyl) -lower alkyl, N(lower alkyl,H) -lower alkyl, nitro, lower alkyl-S(O)2-, carboxy, carboxy-lower alkyl, lower alkyl-COO-lower alkyl, COO- lower alkyl, CO-N(lower alkyl,H) -lower alkyl, CO-N(lower alkyl,lower alkyl) -lower alkyl, CO-NH₂-lower alkyl, lower alkyl-CO- and the like. Preferred substituents are H, F and Me. Preferred "heteroaryl substituted by" are halogen-pyridinyl, fluoro-heteroaryl and fluoro- pyridinyl. Most preferred is 2-fluoro-pyridinyl.

The terms "pharmaceutically acceptable salt" and "pharmaceutically acceptable acid addition salt" embrace salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like. In detail, the present invention relates to compounds of the general formula I,

wherein:

R is Ci-₆-alkyl; Ci-6-alkyl substituted by one 3 to 6 membered monocyclic cycloalkyl or 1 to 3 halogens; Ci-6-alkoxy; aryl; aryl substituted by 1 to 3 halogens; heteroaryl; or heteroaryl substituted by 1 to 3 halogens;

as well as pharmaceutically acceptable salts thereof.

In a preferred embodiment, the present invention relates to a compound of formula I, wherein

R is Ci-6-alkyl optionally substituted by one 3 to 6 membered monocyclic cycloalkyl or 1 to 3 halogens; Ci-6-alkoxy; phenyl substituted by 1 to 3 halogens; or pyridinyl substituted by 1 to 3 halogens;

as well as pharmaceutically acceptable salts thereof.

R is Ci-6-alkyl optionally substituted by one 3 to 6 membered monocyclic cycloalkyl; Ci-6-alkoxy; as well as pharmaceutically acceptable salts thereof.

In a preferred embodiment, the present invention relates to a compound of formula I, wherein R is methyl, ethyl, cyclopropyl-ethyl, methoxy- ethyl, fluoro-methyl, fluorophenyl or fluoro-pyridinyl. In a preferred embodiment the present invention relates e to a compound of formula

(V),

wherein R is defined as given above.

Special preference is given to a compound of formula (V) selected from the group consisting of:

N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl}- acetamide;

N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl} -3- methoxy-propionamide;

N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl}- propionamide;

2-Cyclopropyl-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl } - acetamide; 2-Fluoro-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl } - acetamide;

4-Fluoro-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl} -benzamide; and

6-Fluoro-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl} -nicotinamide.

N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl}- acetamide; N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl} -3- methoxy-propionamide;

2-Cyclopropyl-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl} -acetamide;.

In one embodiment, the invention relates to compounds of formula I wherein R is Ci-6-alkyl optionally substituted by one 3 to 6 membered monocyclic cycloalkyl; or C₁^- alkoxy; as well as pharmaceutically acceptable salts thereof. In one embodiment, the invention relates to compounds of formula I wherein R is Ci-₆-alkyl.

In one embodiment, the invention relates to compounds of formula I wherein R is methyl.

In one embodiment, the invention relates to compounds of formula I wherein R is

Ci-6-alkyl substituted by one 3 to 6 membered monocyclic cycloalkyl or 1 to 3 halogens.

In one embodiment, the invention relates to compounds of formula I wherein R is fluoro-methyl.

In one embodiment, the invention relates to compounds of formula I wherein R is cyclopropyl-ethyl.

In one embodiment, the invention relates to compounds of formula I wherein R is Ci-6-alkoxy.

In one embodiment, the invention relates to compounds of formula I wherein R is ethoxy-ethyl.

In one embodiment, the invention relates to compounds of formula I wherein R is aryl substituted by 1 to 3 halogens.

In one embodiment, the invention relates to compounds of formula I wherein R is fluoro-phenyl.

In one embodiment, the invention relates to compounds of formula I wherein R is heteroaryl substituted by 1 to 3 halogens.

In one embodiment, the invention relates to compounds of formula I wherein R is fluoro-pyridinyl.

A further aspect of the present invention relates to pharmaceutical compositions containing the compounds of formulae (I) and (V) for the treatment of schizophrenia, cognitive disorders and drug addiction.

A further aspect of the present invention relates to a compound of formula I for use as therapeutically active substance.

A further aspect of the present invention relates to a compound of formula I for the treatment or prevention of diseases related to the D3 receptor.

A further aspect of the present invention relates to a method for the therapeutic and/or prophylactic treatment of a disorder or condition mediated by the D3 receptor binding site, or that can be treated via modulation of the D3 receptor binding site, particularly for the therapeutic and/or prophylactic treatment of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, psychoses comprising paranoia and delusions, attention- deficit hyperactivity disorder, addiction and obsessive compulsive disorder, which method comprises administering a compound according to any of claims 1-5 to a human being or animal.

A further aspect of the present invention relates to the process for the manufacture of compounds of formula I as defined above.

The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.

In more detail, the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.

A preferred embodiment of the process for preparing a compound of formula I,

wherein R has the meaning as given above,

comprises one of the following steps:

a) reductive amination of aldehyde of formula (1-1) with 3-piperazine-l-yl- isoxazolo[4,5-c] pyridine of formula (1-2) in the presence of a reducing agent, and

removing the protecting group Boc under acidic conditions to yield amine intermediate of formula (1-3)

b) coupling of amine intermediate of formula (1-3) with a carboxylic acid R-COOH or acid chloride R-COCl to yield compound of formula I.

The ability of the compounds to bind to the D₃ receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.

Biological Data

Membrane preparation for human D₃ receptors

HEK-293 EBNA cells were transiently transfected with expression plasmids encoding for the human D₃ dopamine receptor. The cells were harvested 48 h post-transfection, washed three times with cold PBS and stored at -80⁰C prior to use. The pellet was suspended in cold 50 mM Tris-HCl buffer containing 10 mM EDTA (pH 7.4) and homogenized with a Polytron (Kinematica AG, Basel, Switzerland) for 20-30 sec at 12.000 rpm. After centrifugation at 48.000 X g for 30 min at 4°C, the pellet was resuspended in cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4), homogenized, and centrifuged as above. This pellet was further resuspended in a smaller volume of ice cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4) and homogenized with a Polytron for 20-30 sec at 12.000 rpm. The protein content of this homogenate was determined with the Bio-Rad (Bradford) Protein Assay (Biorad Laboratories GmbH, Mϋnchen, Germany) according to the instructions of the manufacturer using gamma globulin as the standard. This homogenate was stored at -80⁰C in aliquots and thawed immediately prior to use. Radioligand binding assay conditions

Aliquots of membrane preparations were thawed at RT, resuspended in assay buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl₂, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein / well.

The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.5 nM [³H] -spiperone) and ten concentrations of test compound in ranging between 10 μM -0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters (Packard BioScience, Zurich, Switzerland; preincubated for 1 h in 0.1% polyethylenimine (PEI) in assay buffer) with a Filtermate 196 harvester (Packard BioScience) and washed 3 times with cold assay buffer. The nonspecific binding was determined with equally composed reaction mixtures in the presence of 10 μM unlabelled spiperone. Per well 45 μl of Microscint 40 (Perkin Elmer, Schwerzenbach, Switzerland) was added, plates for sealed, shaken for 20 min and counted for 3 min on a Topcount Microplate Scintillation Counter (Canberra Packard SA, Zurich, Switzerland) with quenching correction.

Data calculation

The CPM value for each duplicate of a concentration of competing compound was averaged (yl), then the % specific binding was calculated according to the equation (((yl - non-specific)/(total binding-non-specific) )xl 00). Graphs were plotted with the % specific binding using XLfit, a curve fitting program that iteratively plots the data using Levenburg Marquardt algorithm. The single site competition analysis equation used was y = A + ((B- A)/( l+((x/C)^D))), where y is the % specific binding, A is the minimum y, B is the maximum y, C is the IC50, x is the logio of the concentration of the competing compound and D is the slope of the curve (the Hill Coefficient). From these curves the IC50 (inhibition concentration at which 50% specific binding of the radioligand was displaced) and Hill coefficient were determined. The affinity constant (Ki) was calculated using the Cheng- Prusoff equation Ki = (ICso/l+( [L]/Kd), where [L] is the concentration of radioligand and Kd is the dissociation constant of the radioligand at the receptor as determined by the saturation isotherm.

The compounds of the present invention are potent modulators of the dopamine D₃ receptors as this is shown with the activity table hereinafter which gives the Ki values in μM for the dopamine D₃ receptors for some examples of the compounds of the present invention:

Table 1: acticity table: human Ki values of selected examples The compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such as carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned earlier, medicaments containing a compound of formula I or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.

The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/ day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day. Synthesis

rt

Na(AcO)₃BH, Et₃N

N H Boc CH2CL, rt

(H)

(F) R' = Boc HCI (G) R' = NH. HCI Diox./CH₂CI₂

Scheme 1: General synthesis route

Synthesis of aldehyde (A) is described in Biorg. Med. Chem. Lett 17 (2007), 662-667. (A) is transformed into the corresponding oxime (B), followed by the reaction with tert- butyl 1-piperazinecarboxylate leading to intermediate (C). Ring closure is performed with KOH whereupon intermediate (D) is obtained. After the removal of protecting group Boc, (E) is reacted with trans- [4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester leading to intermediate (G) via (F). The final product is obtained by reacting the free amino function with the desired carboxylic acid. Experimental Part

The following examples are provided to further elucidate the invention.

Example 1

N-{frαM5-4-[2-(4-Isoxazolo[4,5-clpyridin-3-yl-piperazin-l-yl)-ethyll-cyclohexyl}- acetamide

Step 1: 4-Chloro-pyridine-3-carbaldehyde (Intermediate A)

The title compound can be prepared starting from 4-chloropyridine hydrochloride by published methods {Bioorg. Med. Chem. Lett. 17 (2007), 662-667).

Step 2: 4-Chloro-pyridine-3-carbaldehyde oxime (Intermediate B)

4-Chloro-pyridine-3-carbaldehyde (10.0 g, 71 mmol) was dissolved in EtOH (12 ml). H₂O (30 ml), ice (30 g) and hydroxylamine hydrochloride (5.40 g, 78 mmol) were added. To the resulting mixture was added over a period of 2 min a solution of 2 N NaOH (88.3 ml, 177 mmol). The resulting yellowish solution was stirred 2.5 h at r.t. before neutralisation with AcOH (pH = 6). White crystals precipitated, were collected by filtration and washed with H₂O (30 ml). The product was dried 1 h at 50 ⁰C on the high vacuum to yield 9.25 g (84%) of a off white solid, m/z = 157.1 ( [M-H]^"). Step 3: 4-{(4-Chloro-pyridin-3-yl)-[(£,Z)-hydroxyiminol-methyl}-piperazine-l-carboxylic acid tert-butyl ester (Intermediate C)

4-Chloro-pyridine-3-carbaldehyde oxime (4.00 g, 26 mmol) was dissolved in MeCN (40 ml) and N-chlorosuccinimide (3.58 g, 27 mmol) was added in portions (slightly exothermic reaction). The yellowish solution was stirred 30 min more before addition of H₂O and extraction with two portions of EtOAc. The organic layers were washed with more H₂O and brine and dried over Na₂SO/t. The solvent was evaporated to dryness and the residue was dissolved in CH₂Cl₂ (80 ml). Et3N (3.72 ml, 27 mmol) was added to obtain a red solution. tert-Butyl 1-piperazinecarboxylate (5.23 g, 28 mmol) was added in portions and the resulting reaction mixture was stirred 30 min at r.t. Sat. aq. Na₂Cθ3 was added and the product was extracted with CH₂Cl₂. After drying (Na₂SOzO and evaporation of the solvent the product was purified by flash chromatography (100 g SiO₂, Hept/EtOAc 70:30 -> 0:100) yielding 2.37 g (27%) of the title compound as a yellow gum. mlz = 341.1 ( [M+H]⁺).

Step 4: 4-Isoxazolo[4,5-c1pyridin-3-yl-piperazine-l-carboxylic acid tert-butyl ester (Intermediate D)

4-{ (4-Chloro-pyridin-3-yl) - [ (E,Z) -hydroxyimino] -methyl} -piperazine- 1 -carboxylic acid tert-butyl ester (2.36 g, 6.9 mmol) was dissolved in dioxane (20 ml) and 30% aq. KOH (40 ml) was added. After stirring 16 h at 120 ⁰C (reflux) a clear two phases mixture was obtained. After cooling the organic layer was collected and the aqueous phase was extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SOzO and the solvent was evaporated. Flash chromatography (50 g SiO₂, Hept/EtOAc 30:70 -> 0:100) yielded 960 mg (45%) of the title compound as an off white solid, mlz = 305.3 ( [M+H]⁺).

Step 5: 3-Piperazin-l-yl-isoxazolo[4,5-cl pyridine dihydrochloride (Intermediate E)

HCl

^HCI 4-Isoxazolo[4,5-c]pyridin-3-yl-piperazine-l-carboxylic acid tert-butyl ester (960 mg, 3.1 mmol) was dissolved in CH2CI2 (2 ml) and 4 N HCl in dioxane (15.7 ml, 63 mmol) was added. The resulting mixture was stirred 16 h at r.t. After dilution with ¹Pr₂O the product was collected by filtration and washed with one portion of ¹Pr₂O before drying it under high vacuum at 50 ⁰C to obtain 850 mg (97%) as a pink solid, mlz = 205.2 ( [M+H]⁺).

Step 6: {frflπ5-4-[2-(4-Isoxazolo[4,5-clpyridin-3-yl-piperazin-l-yl)-ethyll-cyclohexyl}- carbamic acid tert-butyl ester (Intermediate F)

A solution in CH₂Cl₂ (10 ml) of 3-piperazin-l-yl-isoxazolo[4,5-c] pyridine dihydrochloride (840 mg, 3.0 mmol) and trans- [4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester (904 mg, 3.7 mmol; intermediate H; prepared according to

WO2007/093540) was treated with Et₃N (629 mg, 6.2 mmol) before addition of

Na(AcO)₃BH (1.03 g, 5 mmol). The reaction mixture was stirred 16 h at r.t., then sat. aq.

NaHCO₃ was added and the product was extracted with 2 portions of CH₂Cl₂. After drying (MgSO/t) and evaporation of the solvent the product was purified by flash chromatography

(50 g SiO₂, EtOAc/MeOH 100:0 -> 80:20) to obtain 930 mg (71%) of the title compound as an off white solid, mlz = 430.3 ( [M+H]⁺).

Step 7: frflπ5-4-[2-(4-Isoxazolo[4,5-clpyridin-3-yl-piperazin-l-yl)-ethyll-cyclohexylamine dihydrochloride (Intermediate G)

{frøHs-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl}- carbamic acid tert-butyl ester_(930 mg, 2.2 mmol) was dissolved in CH₂Cl₂ (3 ml) and 4 N HCl in dioxane (10.8 ml, 43 mmol) was added. The resulting mixture was stirred 16 h at r.t. After dilution with ¹Pr₂O the product was collected by filtration and washed with one portion of ¹Pr₂O before drying it under high vacuum at 50 ⁰C to obtain 686 mg (79%) as a white solid, mlz = 330.3 ( [M+H]⁺). Step 8: N-{frflπ5-4-[2-(4-Isoxazolo[4,5-clpyridin-3-yl-piperazin-l-yl)-ethyll-cyclohexyl}- acetamide

A mixture in dioxane (5 ml) of £røHs-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin- 1-yl) -ethyl] -cyclohexylamine dihydrochloride (100 mg, 0.25 mmol), AcOH (22 mg, 0.37 mmol), ¹Pr₂NEt (161 mg, 1.2 mmol) and TBTU (96 mg, 0.30 mmol) was stirred 16 h at r.t. After evaporation to dryness sat. aq. NaHCθ3 was added and the product was extracted with 2 portions of CH₂Cl₂. The organic layers were directly loaded on a column. Flash chromatography (20 g SiO₂, CH₂Cl₂/MeOH 100:0 -> 90:10) yielded 62 mg (67%) of the title compound as white solid, mlz = 372.2 ( [M+H]⁺).

Examples 2-7

Examples 2-7 were prepared in analogy to example 1 starting from trans-4-[2-(4- isoxazolo [4,5-c] pyridin-3-yl-piperazin- 1 -yl) -ethyl] -cyclohexylamine dihydrochloride

(Intermediate G) and an appropriate carboxylic acid.

Table 2: examples 2-7 Pharmaceutical Preparations

Example A

Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

Table 3: Example of film coated tablets

The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.

Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

Table 4: Example of capsules The components are sieved and mixed and filled into capsules of size 2 or another suitable size.

Example C

Injection solutions can have the following composition:

Table 5: Example of injection solutions

Example D

Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:

Table 6: Example of soft gelatin capsules

The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures. Example E

Sachets containing the following ingredients can be manufactured in a conventional manner:

Table 7: Example of sachets

The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.

Claims

1. A compound of formula I:

wherein:

R is Ci-₆-alkyl;

Ci-₆-alkyl substituted by one 3 to 6 membered monocyclic cycloalkyl or 1 to 3 halogens; Ci-₆-alkoxy; aryl; aryl substituted by 1 to 3 halogens; heteroaryl; or heteroaryl substituted by 1 to 3 halogens,

as well as pharmaceutically acceptable salts thereof.

2. A compound of formula I according to claim 1, wherein:

R is Ci-₆-alkyl optionally substituted by one 3 to 6 membered monocyclic cycloalkyl or 1 to 3 halogens; Ci-₆-alkoxy; phenyl substituted by 1 to 3 halogens; or pyridinyl substituted by 1 to 3 halogens;

as well as pharmaceutically acceptable salts thereof.

3. A compound of formula I according to claim 1, wherein:

R is Ci-₆-alkyl optionally substituted by one 3 to 6 membered monocyclic cycloalkyl; Ci-₆-alkoxy; as well as pharmaceutically acceptable salts thereof.

4. A compound of formula I according to any of claims 1-2, wherein R is methyl, ethyl, cyclopropyl-ethyl, methoxy- ethyl, fluoro-methyl, fluorophenyl or fluoro-pyridinyl.

5. A compound of formula (V) according to any of claims 1 to 4:

wherein R is defined as in any of claims 1 to 4.

6. A compound of formula (V) according to claim 5 selected from the group consisting of:

N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexylj-3- methoxy-propionamide; N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl}- propionamide;

2-Cyclopropyl-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl } - acetamide;

2-Fluoro-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl} -acetamide;

6-Fluoro-N-{trans-4- [2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl} -nicotinamide.

7. A compound of formula (V) according to claim 4 selected from the group consisting of:

N-{trans-4-[2-(4-Isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] -cyclohexyl}- propionamide; and

2-Cyclopropyl-N-{trans-4-[2-(4-isoxazolo[4,5-c]pyridin-3-yl-piperazin-l-yl) -ethyl] - cyclohexyl } - acetamide.

8. A process for preparing a compound of formula I

wherein R has the meaning as given in any of claims 1 to 4, comprises one of the following steps: a) reductive amination of aldehyde of formula (1-1) with 3-piperazine-l-yl- isoxazolo(4,5-c] pyridine of formula (1-2) in the presence of a reducing agent, and

b) coupling of amine intermediate of formula (1-3) with a carboxylic acid R- COOH or acid chloride R-COCl to yield compound of formula I₁ wherein R has the meaning as given in any of claims 1 to 4.

9. A compound according to any of claims 1-7 for use as therapeutically active substance.

10. A compound according to any of claims 1-7 for the treatment or prevention of diseases related to the D3 receptor.

RECTIFIED SHEET (RULE 91) ISA/EP

11. A medicament containing one or more compounds as claimed in any one of claims 1 to 5 and pharmaceutically acceptable excipients for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, psychoses comprising paranoia and delusions, attention-deficit hyperactivity disorder, addiction and obsessive compulsive disorder.

12. A compound in accordance with any one of claims 1 to 7 as well as its pharmaceutically acceptable salt for use in the treatment or prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, psychoses comprising paranoia and delusions, attention-deficit hyperactivity disorder, addiction and obsessive compulsive disorder.

13. The use of a compound in accordance with any one of claims 1 to 7 as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, psychoses comprising paranoia and delusions, attention-deficit hyperactivity disorder, addiction and obsessive compulsive disorder

14. A method for the therapeutic and/or prophylactic treatment of a disorder or condition mediated by the D3 receptor binding site, or that can be treated via modulation of the D3 receptor binding site, particularly for the therapeutic and/or prophylactic treatment of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, psychoses comprising paranoia and delusions, attention-deficit hyperactivity disorder, addiction and obsessive compulsive disorder, which method comprises administering a compound according to any of claims 1-7 to a human being or animal.

15. The invention as hereinbefore described.

RECTIFIED SHEET (RULE 91) ISA/EP